FeesSafety
Pluang+

Telomir partners with Linical to start Phase 1/2 trial of Telomir-Zn for triple-negative breast cancer in early 2027

Market News
18 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Telomir partners with Linical to start Phase 1/2 trial of Telomir-Zn for triple-negative breast cancer in early 2027

Telomir Pharmaceuticals has selected Linical, a global CRO with oncology expertise, to support its FDA-cleared Phase 1/2 clinical trial of Telomir-Zn in advanced triple-negative breast cancer. The trial aims to evaluate safety and preliminary efficacy, targeting initiation in Q1 2027. Telomir-Zn is a novel oral therapy designed to modulate metal homeostasis and reactivate tumor suppressor genes, offering a new approach for this aggressive cancer type. This partnership marks a key step toward clinical development and potential new treatment options for patients with limited therapies.

Telomir Pharmaceuticals' clinical trial news provides context for readers following health-sector stocks. On November 18, 2026, out of 150 priced health-sector US stocks tradable on Pluang, 55 rose and 86 fell. Notable movers included SLS at USD 18.61 with a 1-day change of -2.82%, LQDA at USD 55.19 with a 1-day change of -2.71%, and RXRX at USD 2.79 with a 1-day change of +2.57%, as of 19:21 WIB.

More News

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's reported adjusted earnings per share of $3.10, surpassing estimates of $2.88, and revenue of $22.80 billion, beating the $22.40 billion forecast. Comparable sales rose 1.8%, driven by strong online and professional services sales. The company ...

Company Fundamentals
Bullish
49 minutes ago
Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
54 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App